Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

Healthcare Biotechnology
"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

TELESTA THERAPEUTICS INC > The "market" doesn't like the Roth Report..........
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by givmeabrakeon Oct 09, 2015 3:34pm
168 Views
Post# 24180600

RE:RE:RE:The "market" doesn't like the Roth Report..........

RE:RE:RE:The "market" doesn't like the Roth Report..........



Ambitious 40% DFS at one year not met

25% overall Year 1 DFS rate

35% Year 1 DFS rate in patients with papillary tumors only


REMEMBER this was a study done on people who failed current BCG  treatment. 20% DFS response at 1 year IS considered relevant by Urologists - alternative is radical cystectomy!

 

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities